Top Opportunity: Dupixent (dupilumab) represents 90%+ of Patient Finder opportunity in Regeneron's portfolio, with 15-24 million addressable undiagnosed patients in the USA alone across 9 approved indications.
Conservative Revenue Projection: $25-30 million annually at 3% capture rate (USA + DACH + high-income ROW)
Strategic Urgency: HIGH - Dupixent patent expiry 2030-2031 creates 4-5 year window to maximize patient acquisition pre-biosimilar entry
Dupixent (Fit Score: 9/10)
EYLEA HD, Libtayo, Olatorepatide (pipeline)
Specialist-managed, ultra-rare, or lab-based diagnoses
| Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity (5% Capture) |
|---|---|---|---|---|
| Dupixent (dupilumab) | 1 | 9/10 | 15.0-24.4 million | $31.7-50.1 million (USA) $49-55 million (global) |
| EYLEA / EYLEA HD (aflibercept) | 2 | 5/10 | ~321,000 | $12.8 million (USA) $19-23 million (global) |
| Libtayo (cemiplimab) | 2 | 4/10 | ~10,000 | $3.4 million (USA) ~$4 million (global) |
| Linvoseltamab (Lynozyfic) | 3 | 3/10 | ~0 | Not applicable |
| Olatorepatide (PIPELINE) | 2 | 6/10 | 50-70 million | $168-235 million (0.5% capture) |
| Praluent (alirocumab) | NO | 2/10 | Not applicable | Not applicable |
| Kevzara (sarilumab) | NO | 2/10 | Not applicable | Not applicable |
| Evkeeza (evinacumab) | NO | 1/10 | Not applicable | Not applicable |
| Inmazeb (Ebola treatment) | NO | 0/10 | Not applicable | Not applicable |
| Pozelimab (PNH - pipeline) | 3 | 3/10 | ~8,000 | Minimal |
| Odronextamab (no US approval) | NO | N/A | N/A | N/A |
| Fianlimab (Phase 3) | NO | N/A | N/A | N/A |
| Factor XI Antibodies (Phase 2/3) | NO | N/A | N/A | N/A |
| Itepekimab (asthma discontinued) | NO | N/A | N/A | N/A |
Approved Indications: 9 total
Drug Class: Fully human monoclonal antibody targeting IL-4 receptor alpha (IL-4Rα), blocking IL-4 and IL-13 signaling
Commercial Status: Blockbuster; $17.8B global net sales (2025), +26% YoY
| Indication | Total Prevalent (USA) | Undiagnosed | Drug-Addressable Undiagnosed |
|---|---|---|---|
| Atopic Dermatitis | 32.9 million | 16.3 million (50%) | 5.4-6.0 million (mod-severe) |
| Chronic Spontaneous Urticaria | 2.6 million | 1.96 million (75%) | 1.18 million |
| Prurigo Nodularis | 142,000 | 71,000 (50%) | 60,000 |
| Eosinophilic Esophagitis | 142,000 | 57,000 (40%) | 51,300 |
| Asthma (eosinophilic) | 31.1 million total | 9.3 million (30%) | 1.0-1.5 million |
| COPD (eosinophilic) | 67 million total | 50.25 million (75%) | 5-8 million |
| CRSwNP | 6.7 million | 2.01 million (30%) | 1.81 million |
| AFRS | 2.76 million | 552,000 (20%) | 386,000 |
| Bullous Pemphigoid | 158,000 | 24,000 (15%) | 21,600 |
| TOTAL | ~147 million | ~80 million | 15.0-24.4 million |
26 doses × $4,193.03
After 50% rebates (midpoint)
Per patient found
US & EU
| Metric | USA | DACH | Global (Conservative) |
|---|---|---|---|
| Drug-Addressable Undiagnosed | 15.0-24.4 million | ~3.4 million | 30-40 million |
| Net Revenue/Patient | $54,509 | $40,837 | $30,000 avg |
| Ada Revenue @ 1% Capture | $6.3-10.0M | $1.1M | $9.8-11.0M |
| Ada Revenue @ 5% Capture | $31.7-50.1M | $5.6M | $49-55M |
| Ada Revenue @ 3% Capture (Conservative) | $19.0-30.1M | $3.4M | $25-30M |
Excellent pattern recognition for chronic itch, rash, hives
Patent cliff urgency; $17.8B revenue at stake
TIER 1: PURSUE AGGRESSIVELY
Dupixent represents the single largest Patient Finder opportunity in Regeneron's portfolio. With 60% of atopic dermatitis cases globally undiagnosed (133 million patients), median 4-year diagnostic delays in eosinophilic esophagitis, 1.7-2.5 year delays before specialized urticaria therapy, and 70-90% COPD underdiagnosis, Ada's symptom assessment engine can identify characteristic Type 2 inflammatory patterns—chronic itch and rash in AD, recurrent unprovoked hives in CSU, intense nodular pruritus in PN—at a scale unreachable by traditional physician screening. At $54,509 net revenue per patient annually in the U.S. (after rebates), even a 1% improvement in diagnostic rates across Dupixent-eligible populations could generate $6-10 million in Ada revenue (8-12% of first-year drug revenue) while dramatically improving patient outcomes for conditions causing profound quality-of-life impairment. With Dupixent's patent expiring in 2030-2031, the next 4-5 years are strategically critical for Regeneron and Sanofi to maximize patient acquisition, creating an urgent, high-value partnership opportunity where Ada's digital patient finding capabilities directly address a multi-billion-dollar market expansion imperative.
Approved Indications: Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Retinal Vein Occlusion (RVO)
Drug Class: Recombinant fusion protein (anti-VEGF)
Commercial Status: Declining; Q4 2025 combined U.S. net sales $1.1B (-28% YoY); EYLEA HD $506M (+66% YoY)
| Metric | Value |
|---|---|
| Addressable Undiagnosed (USA) | ~321,000 (wet AMD) |
| Net Revenue/Patient/Year | $8,000-12,000 |
| Ada Revenue @ 5% Capture (USA) | $12.8 million |
| Ada Surface Ability | 4/10 |
| Company Motivation | 5/10 |
| Overall Fit Score | 5/10 |
Diagnosis requires imaging: OCT imaging and fluorescein angiography are necessary for wet AMD diagnosis. Vision changes are alarming and typically prompt ophthalmology referral without digital intervention. The primary barrier is underdiagnosis in primary eye care (25% of AMD cases despite dilated exams), suggesting that screening programs with portable imaging (teleophthalmology) would deliver higher ROI than symptom checkers alone.
Recommendation: DEPRIORITIZE unless integrated into teleophthalmology screening programs with imaging partnerships
Approved Indications: Cutaneous Squamous Cell Carcinoma (CSCC - advanced/metastatic and adjuvant high-risk), Basal Cell Carcinoma (BCC), Non-Small Cell Lung Cancer (NSCLC)
Drug Class: PD-1 inhibitor (immune checkpoint inhibitor)
Commercial Status: Growing; global sales $425 million (Q4 2025, +16% YoY); projected >$2B annually by 2027-2028
| Metric | Value |
|---|---|
| Addressable Undiagnosed (USA) | ~10,000 (advanced CSCC + NSCLC) |
| Net Revenue/Patient/Year | $82,642 |
| Ada Revenue @ 5% Capture (USA) | $3.4 million |
| Ada Surface Ability | 2/10 |
| Company Motivation | 4/10 |
| Overall Fit Score | 4/10 |
Indication mismatch: Libtayo is indicated only for advanced/unresectable CSCC (~8,000 undiagnosed) and adjuvant high-risk post-surgery/radiation (patients already diagnosed and in oncology care). Ada's role in earlier CSCC detection (identifying non-healing skin lesions) would surface patients for surgical excision, not immunotherapy. Advanced CSCC patients are typically already under oncology management by the time Libtayo becomes indicated.
Recommendation: DEPRIORITIZE for direct Patient Finder partnership; consider as ancillary benefit of broader skin cancer awareness initiatives
Approved Indication: Relapsed/Refractory Multiple Myeloma (r/r MM) after ≥4 prior lines of therapy
Drug Class: BCMA x CD3 bispecific T-cell engager
Commercial Status: FDA accelerated approval July 2025; revenue not separately disclosed (launch phase)
| Metric | Value |
|---|---|
| Addressable Undiagnosed | ~0 |
| Ada Revenue Opportunity | Not applicable |
| Ada Surface Ability | 0/10 |
| Company Motivation | 2/10 |
| Overall Fit Score | 3/10 |
Diagnosed, specialist-managed population: Linvoseltamab is indicated for heavily pretreated r/r MM patients (≥4 prior lines). These are diagnosed patients already under hematology/oncology care. Multiple myeloma diagnosis requires blood tests (M-protein, serum free light chains) and bone marrow biopsy—not symptom-based assessment.
Recommendation: NOT SUITABLE FOR PATIENT FINDER
Indication: Obesity (Phase 3 in 2026)
Drug Class: Dual GLP-1/GIP receptor agonist
Commercial Status: Phase 3 China trial completed (19.3% weight loss at 48 weeks); global Phase 3 registrational program to initiate 2026
| Subpopulation | Addressable (USA) | Differentiation |
|---|---|---|
| Sarcopenic Obesity | 16-21 million | Muscle-preserving GLP-1 + antibodies |
| Obesity + Hyperlipidemia | 52 million | Olatorepatide + Praluent coformulation |
| Combined (overlap) | 50-70 million | Dual differentiation |
| Capture Rate | Patients | Ada Revenue (USA) |
|---|---|---|
| 0.1% | 50,000-70,000 | $33.6-47 million |
| 0.5% | 250,000-350,000 | $168-235 million |
Note: Obesity market scale requires lower capture rate assumptions (0.1-0.5%) vs. rare diseases (1-5%)
Can identify obesity comorbidities, muscle complaints
Obesity market >$100B; late to market needs edge
TIER 2: POST-APPROVAL
Phase 3 initiation: 2026
Projected approval: 2027-2028
Contingency: Partnership opportunity contingent on proven differentiation (muscle preservation + lipid benefits) in Phase 3 trials vs. Zepbound/Wegovy
Recommendation: MONITOR Phase 3 data; initiate partnership discussions post-approval if muscle preservation and lipid benefits confirmed
| Drug | Indication | Fit Score | Why Not Suitable |
|---|---|---|---|
| Praluent (alirocumab) | Hypercholesterolemia, Familial Hypercholesterolemia | 2/10 | Asymptomatic condition; diagnosed via blood test (lipid panel), not symptoms |
| Kevzara (sarilumab) | Rheumatoid Arthritis | 2/10 | Diagnosis requires serology (RF, anti-CCP), imaging, rheumatology evaluation |
| Evkeeza (evinacumab) | Homozygous Familial Hypercholesterolemia | 1/10 | Ultra-rare orphan drug (1 in 160,000-300,000); diagnosed patients already identified |
| Inmazeb | Ebola Virus Disease | 0/10 | Outbreak drug; infectious disease requiring immediate medical intervention in outbreak contexts |
| Pozelimab + Cemdisiran | Paroxysmal Nocturnal Hemoglobinuria (pipeline) | 3/10 | Ultra-rare (~16,000 diagnosed in 7MM); requires flow cytometry; specialist-managed |
| Odronextamab (Ordspono) | Relapsed/Refractory Follicular Lymphoma | N/A | FDA CRL issued July-August 2025 due to manufacturing issues; no US approval timeline |
| Fianlimab + Cemiplimab | Melanoma (Phase 3) | N/A | Phase 3 trials ongoing; 2-3 years from potential launch |
| Factor XI Antibodies | Anticoagulation, VTE prevention (Phase 2/3) | N/A | Phase 2 completed; broad Phase 3 program beginning 2025; 2-3+ years from approval |
| Itepekimab | Asthma (DISCONTINUED); CRSwNP (Phase 3) | N/A | Asthma program halted 2021; redirected to other indications in early-stage development |
Of Patient Finder opportunity in Regeneron portfolio
Until 2030-2031 biosimilar entry
16.3 million undiagnosed in USA
1.96 million undiagnosed in USA